Organogenesis offers products across all FDA classifications.
1 report, 1 independent
Updated Aug 8
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Organogenesis offers products across all FDA classifications.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Organogenesis (United States)
company in Canton, United States
Nothing else this week.
Related events
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.
- FDA failed to update warning labels despite confirmed risks associated with a product.
- FDA oversees drug trials in the US and Israel for Clearmind Medicine Inc., which is listed on Nasdaq.
- The Food and Drug Administration (FDA) oversees product safety and recalls.
- Tarsus Pharmaceuticals is seeking FDA approval in the US and is listed on the Nasdaq stock exchange.
Coverage
Newest first; wire copies grouped- GlobeNewswireOrganogenesis Holdings Inc. Reports Second Quarter 2025 Financial Results CANTON, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine